PCOS Has a New Name. Here Is What PMOS Means for You.
By Dr. Anindo Mitra, Consultant Psychiatrist, Athena Behavioural Health, Gurugram
TL;DR
PCOS (polycystic ovary syndrome) has officially been renamed PMOS: polyendocrine metabolic ovarian syndrome
The "cysts" in the old name were never actually pathological ovarian cysts, making the name clinically misleading for decades
PMOS is now understood as a full-body hormonal and metabolic condition, not just an ovarian or fertility problem
Insulin resistance is present in 85% of people with PMOS, including 75% of lean women with the condition
The name change comes from a Lancet-published global consensus process involving 14,360 survey responses and 56 international organisations
Introduction
If you have been told you have PCOS, there is a good chance the name itself confused you. Polycystic ovary syndrome. It sounds like there are cysts on your ovaries. Many women spend years believing that. Some get unnecessary anxiety about cysts that were never really there. Others never connect their weight gain, fatigue, mood shifts, or blood sugar problems to the same condition.
A paper published in The Lancet in May 2026 has officially changed the name to PMOS: polyendocrine metabolic ovarian syndrome. This is not a cosmetic update. The name change reflects a fundamental shift in how medicine now understands this condition, what it actually is, and why so many women with it have spent years feeling dismissed, undiagnosed, or confused about what is happening in their bodies.
Why Was the Old Name Misleading?
The term "polycystic ovary" implies the presence of pathological cysts on the ovaries. According to the Lancet paper, those cysts are not actually a feature of the condition. What appears on an ultrasound as a "polycystic" pattern is really a collection of small undeveloped follicles, not true ovarian cysts. This distinction matters.
When a name implies something that is not there, it creates real-world consequences. The Lancet authors document several: up to 70% of people with this condition remain undiagnosed, many clinicians still think of it primarily as a fertility problem, and patients often receive fragmented care from multiple specialists who are not communicating with each other. The confusion is not just semantic. It changes which doctors someone sees, which symptoms get taken seriously, and how quickly a diagnosis is reached.
What PMOS Actually Is: A Whole-Body Condition
PMOS is a polyendocrine, metabolic, and ovarian syndrome. Each word in that name earns its place.
Polyendocrine means multiple hormonal systems are involved, not just the ovaries. The condition involves disturbances in insulin, androgens (male-type hormones that everyone produces in varying amounts), gonadotropins, and neuroendocrine signalling pathways. These are not secondary complications. They are central to the condition.
Metabolic reflects the fact that insulin resistance is present in approximately 85% of people with PMOS, and in 75% of lean women with the condition. This is one of the most clinically important findings in the Lancet paper. Many women with PMOS are told they cannot have it because they are not overweight. The data says otherwise. Insulin resistance in PMOS is a biological feature of the condition itself, not simply a consequence of weight.
The metabolic dimension also explains why PMOS carries increased risks of type 2 diabetes, high blood pressure, dyslipidaemia, and cardiovascular disease. According to the 2023 International Evidence-Based Guideline for PCOS, women with this condition have a 1.68 times higher odds of cardiovascular disease, 2.50 times higher odds of myocardial infarction, and 1.71 times higher odds of stroke compared to women without it. These are not distant future risks. They are present-day clinical concerns that need monitoring and management.
Ovarian is retained in the name because ovarian dysfunction remains a defining feature. The ovaries are involved. Follicular development is disrupted. Ovulatory function is affected. The ovaries are not the cause of everything, but they are part of the picture.
Who Gets PMOS?
PMOS affects approximately 1 in 8 women during their reproductive years. Globally, that is more than 170 million people. In India, estimates suggest it affects 9 to 22% of women of reproductive age, making it among the most common endocrine conditions in the country.
Despite this scale, up to 70% of affected individuals remain undiagnosed. That gap comes from several places: the misleading name, clinicians who still frame it primarily as a fertility problem, and women who present with symptoms that do not look like the textbook picture of irregular periods and polycystic ovaries.
The condition can present as acne that does not respond to dermatological treatment. It can present as hair thinning or excess facial hair. It can present as fatigue, weight gain despite normal eating, difficulty concentrating, low mood, or anxiety. It can present as irregular periods, but also as periods that look regular on the surface while ovulation is still not happening reliably.
Why Does the Name Change Matter for Your Care?
The Lancet authors argue that inaccurate medical language changes patient outcomes. That is worth sitting with for a moment.
When a condition is named after one organ, clinicians route patients to that specialty. Gynaecologists treat cycles and fertility. Endocrinologists treat insulin and metabolism. Cardiologists treat cardiovascular risk. Dermatologists treat acne and hair changes. Psychiatrists and psychologists are rarely in the conversation at all, despite the significant mental health burden associated with PMOS. The result is fragmented care, where no one person is managing the whole condition.
A name that reflects the true multisystem nature of PMOS changes that framing. It signals to clinicians that this condition needs coordinated, multidisciplinary management, not a series of disconnected specialist visits. It changes what gets screened for, how urgently, and how often.
For patients, it changes the conversation you can have with your doctor. You are not there to discuss ovarian cysts. You are there to discuss your insulin sensitivity, your cardiovascular risk, your mental health, your thyroid, your fertility if relevant, and your long-term metabolic trajectory.
What Changes Practically?
The transition to the new name will happen over a three-year period. The 2028 update of the International Guidelines will incorporate PMOS. Electronic medical records, ICD coding, and clinical education will be updated progressively.
For now, your doctor may still use PCOS. That is fine. The condition is the same. What has changed is how medicine officially understands and frames it. If you have been diagnosed with PCOS and have not had your insulin resistance assessed, have not had cardiovascular risk factors checked, and have not had a conversation about mental health, ask for these. The new name gives you the language to ask.
FAQ
Is PCOS and PMOS the same condition?
Yes. PMOS is the new official name for what was previously called PCOS. The condition itself has not changed. The name has been updated to more accurately reflect what the condition actually involves.
Do I need to get re-diagnosed now that the name has changed?
No. If you have a diagnosis of PCOS, that diagnosis stands. You do not need any new tests purely because of the name change.
Does PMOS mean I definitely have ovarian cysts?
No. The original name was misleading on this point. What appears as a "polycystic" pattern on ultrasound is a collection of small undeveloped follicles, not true pathological cysts. Many women with PMOS have a normal-appearing ultrasound.
I am lean and was told I cannot have PCOS. Is that accurate?
This is one of the most common misconceptions. Insulin resistance, the central metabolic feature of PMOS, is present in 75% of lean women with the condition. Weight is not a diagnostic criterion. If you have symptoms and have been dismissed because of your weight, it is worth seeking a second opinion.
Is PMOS just a fertility problem?
No. Fertility is one aspect of the condition in some women, but PMOS has metabolic, cardiovascular, psychological, and dermatological dimensions that persist across the lifespan, including after menopause.
Should I be worried about heart disease?
The data shows that women with PMOS have increased cardiovascular risk compared to those without the condition. This does not mean heart disease is inevitable. It means cardiovascular risk factors should be monitored and addressed as part of routine PMOS care.
What kind of doctor should I see for PMOS?
Ideally, a physician who can assess the full picture: hormonal function, metabolic health, and mental health. In practice, this might be an endocrinologist or a gynaecologist with interest in metabolic health. Psychiatrists or psychologists should be part of the care team when depression, anxiety, or eating difficulties are present.
